Hybridoma Generation for Therapeutic Antibody Discovery

Hybridoma Generation for Therapeutic Antibody Discovery 

Hybridoma technology and development is a critical step on the path towards therapeutic mAb discovery and antibody drug lead generation. Our Hybridoma Generation for Therapeutic Antibody Discovery Service starts by selecting from a portfolio of immunization approaches to insure robust and appropriate immune responses. The combination of optimized immunization, fusion, and functional screening assays yields up to 100 high quality clonal hybridomas, assuring the success of your antibody drug discovery from the very beginning. 

SERVICE FLOWCHART

Key Features of Premium Hybridoma Development Services

1. One stop solution: from antigen production to hybridoma development and characterization.

2. Full spectrum of immunization approaches: protein, peptide, whole cells and DNA immunization.

3. High throughput screening: Proprietary NativeSelect™ ELISA or HT March™ for high efficiency screening.

4. Comprehensive functional assay: Validated functional assay platforms provide reliable in vitro screening.

5. Readily integrated downstream services: Ab sequencing, Ab humanization, rAb production and anti-idiotype antibodies for your Ab drug PD/PK studies.